However, in vivo and in vitro experiments have shown that activation of toll-like receptor 8 (TLR8) signaling can block this mechanism to suppress T lymphocyte senescence and enhance antitumor immunity in the microenvironment, providing a new strategy for tumor immunotherapy [72,73]. The gene discussed is TLR8; the disease is neoplasm.